Disease · EFO_0004517
arterial stiffness measurement
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. arterial stiffness measurement. Diseases, record EFO_0004517. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004517
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- arterial stiffness measurement
- Open Targets ID
- EFO_0004517
- Other names
- arterial stiffness
- Highest stage of its drugs
- Phase 3, for 3 of its 15 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs15
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EPLERENONE | CHEMBL1095097 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRBESARTAN | CHEMBL1513 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LINAGLIPTIN | CHEMBL237500 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMILORIDE | CHEMBL945 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NICOTINAMIDE RIBOSIDE | CHEMBL438497 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALLOPURINOL | CHEMBL1467 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALISKIREN | CHEMBL1639 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ESTRADIOL | CHEMBL135 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 15
See all 15 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 2 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 2 | Dipeptidyl peptidase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| ABCC8 | Sulfonylurea receptor 1, Kir6.2 | 1 | Sulfonylurea receptor 1, Kir6.2 blocker | Unknown | https://conductscience.org/library/genes/6833 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha agonist | Unknown | https://conductscience.org/library/genes/2099 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 1 | Gonadotropin-releasing hormone receptor antagonist | Unknown | https://conductscience.org/library/genes/2798 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| KCNJ11 | Sulfonylurea receptor 1, Kir6.2 | 1 | Sulfonylurea receptor 1, Kir6.2 blocker | Unknown | https://conductscience.org/library/genes/3767 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Phase 3 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| REN | Renin | 1 | Renin inhibitor | Unknown | https://conductscience.org/library/genes/5972 | Drugs and targets |
| SCNN1A | Amiloride-sensitive sodium channel, ENaC | 1 | Amiloride-sensitive sodium channel, ENaC blocker | Phase 2/3 | https://conductscience.org/library/genes/6337 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00608062 | Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women | Not applicable | 155 | 2020-12-24 | Arterial Stiffening, Aging, Menopause | ESTRADIOL, GANIRELIX ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT03837626 | ENAC Blockade and Arterial Stiffness | Phase 2/3 | 137 | 2025-12-30 | Overweight and Obesity, Insulin Resistance | AMILORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03648996 | Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid | Phase 2 | 34 | 2023-07-03 | Diabetes Mellitus, Type 2, Hyperuricemia | ALLOPURINOL | Its record names the disease | ClinicalTrials.gov |
| NCT03821623 | Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults | Phase 2 | 118 | Hypertension, Aging | NICOTINAMIDE RIBOSIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04040959 | Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD | Phase 2 | 118 | Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress | NICOTINAMIDE RIBOSIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00791830 | Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan | Phase 3 | 82 | Kidney Failure, Chronic | IRBESARTAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00696982 | The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation | Not applicable | 60 | Diabetes Mellitus, Arterial Stiffness | GLYBURIDE, SITAGLIPTIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07328100 | Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. | Not applicable | 60 | Vascular Aging, NAD | NADIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04472637 | Atorvastatin Effects On Arterial Stiffness In Hemodialysis | Phase 2 | 50 | Arterial Stiffness | ATORVASTATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06745063 | Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity | Phase 2 | 50 | Obesity, Vascular Health | EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Amiloride vs Placebo: deaths from any cause | 0 of 90 | 0 of 47 | 137 | NCT03837626 | Trial comparisons |
| Amiloride vs Placebo: serious adverse events | 0 of 90 | 0 of 47 | 137 | NCT03837626 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 22969140 | RESULT | 1 | PubMed |
| 41264372 | DERIVED | 2 | PubMed |
| 41204172 | DERIVED | 1 | PubMed |
| 39082471 | DERIVED | 1 | PubMed |
| 35620522 | DERIVED | 1 | PubMed |
| 35585282 | DERIVED | 1 | PubMed |
| 33115436 | DERIVED | 1 | PubMed |
| 31604171 | DERIVED | 1 | PubMed |
| 27281773 | DERIVED | 1 | PubMed |
| 26030651 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0004517
GET https://conductscience.org/api/diseases/v1/EFO_0004517/drugs